A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal Article
Prognostic Value of Bone Marrow Angiogenesis in Multiple Myeloma
S V Rajkumar,T Leong,Patrick C. Roche,R Fonseca,Angela Dispenzieri,Martha Q. Lacy,John A. Lust,Thomas E. Witzig,Robert A. Kyle,Morie A. Gertz,P R Greipp +10 more
TL;DR: It is concluded that bone marrow angiogenesis is a predictor of poor survival in newly diagnosed myeloma and a simple visual grading of angiogenic is an efficient alternative to microvessel density estimation.
Journal ArticleDOI
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri,Robert A. Kyle,Jerry A. Katzmann,Terry M. Therneau,Dirk R. Larson,Joanne T. Benson,Raynell J. Clark,L. Joseph Melton,Morie A. Gertz,Shaji Kumar,Rafael Fonseca,Diane F. Jelinek,S. Vincent Rajkumar +12 more
TL;DR: The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM and is incorporated into the risk model, where 5-year progression rates in high, intermediate, and low-risk groups were 76%, 51%, and 25%, respectively.
Journal ArticleDOI
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
Morie A. Gertz,Martha Q. Lacy,Angela Dispenzieri,Philip R. Greipp,Mark R. Litzow,Kimberly J. Henderson,Scott Van Wier,Greg J. Ahmann,Rafael Fonseca +8 more
TL;DR: For high-dose therapy patients, -17(p13) and t(4;14) have clinical importance for estimating time to progression and overall survival and the presence of t( 4; 14) identifies a subset of patients whose time to progress is only 8.2 months.
Journal ArticleDOI
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
Robert A. Kyle,Dirk R. Larson,Terry M. Therneau,Angela Dispenzieri,Shaji Kumar,James R. Cerhan,S. Vincent Rajkumar +6 more
TL;DR: Overall survival was shorter among patients with MGUS than was expected in a matched control population and the presence of two adverse risk factors — namely, an abnormal serum free light‐chain ratio and a high serum monoclonal protein level — was associated with a risk of progression at 20 years.
Journal ArticleDOI
Diagnosis of monoclonal gammopathy of renal significance
Frank Bridoux,Nelson Leung,Colin A. Hutchison,Guy Touchard,Sanjeev Sethi,Jean Paul Fermand,Maria M. Picken,Guillermo A. Herrera,Efstathios Kastritis,Giampaolo Merlini,Murielle Roussel,Fernando C. Fervenza,Angela Dispenzieri,Robert A. Kyle,Samih H. Nasr +14 more
TL;DR: This review addresses the pathologic and clinical features of MGRS lesions, indications of renal biopsy, and a proposed algorithm for the hematologic workup.